Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015
Summary
Global Markets Directs, Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news and deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and RandD brief, licensing and collaboration details and other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective RandD development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Chronic Kidney Disease (Chronic Renal Failure) Overview 11
Therapeutics Development 12
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 12
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 13
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 14
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 17
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 22
Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 25
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 26
Acceleron Pharma, Inc. 26
AFFiRiS AG 27
Angion Biomedica Corp. 28
Astellas Pharma Inc. 29
Bayer AG 30
Bio-inRen 31
Boryung Pharmaceutical Co., Ltd. 32
Celtic Biotech, Ltd. 33
Concert Pharmaceuticals, Inc. 34
Eli Lilly and Company 35
Evotec AG 36
Intercept Pharmaceuticals, Inc. 37
La Jolla Pharmaceutical Company 38
Multi Gene Vascular Systems Ltd 39
Nippon Zoki Pharmaceutical Co., Ltd. 40
OPKO Health, Inc. 41
Otsuka Holdings Co., Ltd. 42
Prolong Pharmaceuticals 43
ProMetic Life Sciences Inc. 44
Quark Pharmaceuticals, Inc. 45
Reata Pharmaceuticals, Inc. 46
Red Glead Discovery AB 47
Resverlogix Corp. 48
Sphaera Pharma Pvt. Ltd. 49
Stelic Institute Co. 50
Toray Industries, Inc. 51
VBS Pharmaceuticals 52
Vicore Pharma AB 53
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 57
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
ANG-3070 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RD Progress 63
ANG-3557 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RD Progress 64
ANG-4011 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RD Progress 65
AS-2444697 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RD Progress 66
ASP-6858 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RD Progress 67
bardoxolone methyl - Drug Profile 68
Product Description 68
Mechanism of Action 68
RD Progress 68
beraprost sodium SR - Drug Profile 71
Product Description 71
Mechanism of Action 71
RD Progress 71
BR-05001 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RD Progress 74
BRN-1889 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RD Progress 75
C-21 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RD Progress 76
calcifediol - Drug Profile 78
Product Description 78
Mechanism of Action 78
RD Progress 78
CAR Peptide - Drug Profile 80
Product Description 80
Mechanism of Action 80
RD Progress 80
Cardiotoxin - Drug Profile 81
Product Description 81
Mechanism of Action 81
RD Progress 81
CTP-499 - Drug Profile 82
Product Description 82
Mechanism of Action 82
RD Progress 82
CXA-10 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RD Progress 84
Drug for Kidney Diseases - Drug Profile 85
Product Description 85
Mechanism of Action 85
RD Progress 85
Drugs to Inhibit CYP24 for CKD and Pre-CKD - Drug Profile 86
Product Description 86
Mechanism of Action 86
RD Progress 86
INT-767 - Drug Profile 87
Product Description 87
Mechanism of Action 87
RD Progress 87
LJPC-101 - Drug Profile 89
Product Description 89
Mechanism of Action 89
RD Progress 89
LY-3016859 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RD Progress 90
LY-3113593 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RD Progress 91
MultiGeneGraft - Drug Profile 92
Product Description 92
Mechanism of Action 92
RD Progress 92
NZ-419 - Drug Profile 94
Product Description 94
Mechanism of Action 94
RD Progress 94
PBI-4050 - Drug Profile 96
Product Description 96
Mechanism of Action 96
RD Progress 96
Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 97
Product Description 97
Mechanism of Action 97
RD Progress 97
rivaroxaban - Drug Profile 98
Product Description 98
Mechanism of Action 98
RD Progress 98
RNAi Oligonucleotide for Chronic Diseases - Drug Profile 103
Product Description 103
Mechanism of Action 103
RD Progress 103
RVX-208 - Drug Profile 104
Product Description 104
Mechanism of Action 104
RD Progress 104
Sanguinate - Drug Profile 106
Product Description 106
Mechanism of Action 106
RD Progress 106
Small Molecule to Inhibit Sodium-Phosphate Cotransport for CKD and Hypertension - Drug Profile 108
Product Description 108
Mechanism of Action 108
RD Progress 108
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 109
Product Description 109
Mechanism of Action 109
RD Progress 109
Small Molecules for Chronic Kidney Disease - Drug Profile 110
Product Description 110
Mechanism of Action 110
RD Progress 110
Small Molecules for Chronic Kidney Disease - Drug Profile 111
Product Description 111
Mechanism of Action 111
RD Progress 111
sotatercept - Drug Profile 112
Product Description 112
Mechanism of Action 112
RD Progress 112
SP-20103 - Drug Profile 115
Product Description 115
Mechanism of Action 115
RD Progress 115
SphK2 Program - Drug Profile 116
Product Description 116
Mechanism of Action 116
RD Progress 116
SPR-494 - Drug Profile 117
Product Description 117
Mechanism of Action 117
RD Progress 117
STNM-310 - Drug Profile 118
Product Description 118
Mechanism of Action 118
RD Progress 118
tolvaptan - Drug Profile 119
Product Description 119
Mechanism of Action 119
RD Progress 119
TRC-101 - Drug Profile 121
Product Description 121
Mechanism of Action 121
RD Progress 121
Vaccine for Chronic Kidney Disease - Drug Profile 122
Product Description 122
Mechanism of Action 122
RD Progress 122
Vida-5 - Drug Profile 123
Product Description 123
Mechanism of Action 123
RD Progress 123
Chronic Kidney Disease (Chronic Renal Failure) - Recent Pipeline Updates 124
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 157
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 159
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 160
Featured News Press Releases 160
Apr 07, 2015: Resverlogix Receives Two Patents For RVX-208 In China 160
Mar 27, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings 160
Mar 19, 2015: Prometic Successfully Completes Its Pbi-4050 Phase Ib In Patients With Chronic Kidney Disease 160
Mar 06, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference 161
Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 161
Oct 22, 2014: Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder 162
Aug 11, 2014: Rayaldee Phase 3 Trial Meets Primary Endpoints 162
Jul 02, 2014: Future Development Direction for Bardoxolone Methyl (RTA 402) 163
Jun 18, 2014: ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial 164
May 06, 2014: OPKO Completes Patient Enrollment in Third Phase 3 Trial of RAYALDEE 164
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 166
Disclaimer 167
List Of Tables
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2015 12
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Development by Companies, H1 2015 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Late Stage Development, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Comparative Analysis by Unknown Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H1 2015 26
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AFFiRiS AG, H1 2015 27
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H1 2015 28
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H1 2015 29
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2015 30
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H1 2015 31
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2015 32
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Celtic Biotech, Ltd., H1 2015 33
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 34
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eli Lilly and Company, H1 2015 35
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1 2015 36
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 37
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2015 38
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 39
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H1 2015 40
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health, Inc., H1 2015 41
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 42
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals, H1 2015 43
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc., H1 2015 44
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 45
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 46
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H1 2015 47
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp., H1 2015 48
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015 49
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute Co., H1 2015 50
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H1 2015 51
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VBS Pharmaceuticals, H1 2015 52
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1 2015 53
Assessment by Monotherapy Products, H1 2015 54
Number of Products by Stage and Target, H1 2015 56
Number of Products by Stage and Mechanism of Action, H1 2015 58
Number of Products by Stage and Route of Administration, H1 2015 60
Number of Products by Stage and Molecule Type, H1 2015 62
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Recent Pipeline Updates, H1 2015 124
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2015 157
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..1), H1 2015 158
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2015 159
List Of Figures
List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2015 12
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Products, H1 2015 20
Assessment by Monotherapy Products, H1 2015 54
Number of Products by Top 10 Targets, H1 2015 55
Number of Products by Stage and Top 10 Targets, H1 2015 55
Number of Products by Top 10 Mechanism of Actions, H1 2015 57
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 57
Number of Products by Top 10 Routes of Administration, H1 2015 59
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 60
Number of Products by Top 10 Molecule Types, H1 2015 61
Number of Products by Stage and Top 10 Molecule Types, H1 2015 62
